Abstract
Background
We aim to review the clinical features of two renal tubular disorders characterized by sodium and potassium wasting: Bartter syndrome and Gitelman syndrome.
Data sources
Selected key references concerning these syndromes were analyzed, together with a PubMed search of the literature from 2000 to 2011.
Results
The clinical features common to both conditions and those which are distinct to each syndrome were presented. The new findings on the genetics of the five types of Bartter syndrome and the discrete mutations in Gitelman syndrome were reviewed, together with the diagnostic workup and treatment for each condition.
Conclusions
Patients with Bartter syndrome types 1, 2 and 4 present at a younger age than classic Bartter syndrome type 3. They present with sypmtoms, often quite severe in the neonatal period. Patients with classic Bartter syndrome type 3 present later in life and may be sporadically asymptomatic or mildly symptomatic. The severe, steady-state hypokalemia in Bartter syndrome and Gitelman syndrome may abruptly become lifethreatening under certain aggravating conditions. Clinicians need to be cognizant of such renal tubular disorders, and promptly treat at-risk patients.
Similar content being viewed by others
References
Bartter FC, Pronove P, Gill JR Jr, MacCardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 1962;33:811–828.
Gill JR Jr, Bartter FC. Evidence for a prostaglandin-independent defect in chloride reabsorption in the loop of Henle as a proximal cause of Bartter’s syndrome. Am J Med 1978;65:766–772.
Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 1966;79:221–235.
Seyberth HW. An improved terminology and classification of Bartter-like syndromes. Nat Clin Pract Nephrol 2008;4:560–567.
Chan JC, Gill JR Jr, Bartter FC. Lack of evidence for a role of prostaglandin in the mediation of impaired urinary concentrating ability in Bartter’s syndrome. Nephron 1983;35:116–119.
Roth KS, Ward RJ, Chan JCM, Sarafoglou K. Disorders of calcium, phosphate, and bone metabolism. In: Sarafoglou K, Hoffmann GF, Roth KS, eds. Pediatric Endocrinology and Inborn Errors of Metabolism. New York: McGraw Hill Medical Publishers, 2009: 619–664.
Fukuyama S, Okudaira S, Yamazato S, Yamazato M, Ohta T. Analysis of renal tubular electrolyte transporter genes in seven patients with hypokalemic metabolic alkalosis. Kidney Int 2003;64:808–816.
Bailey MA, Cantone A, Yan Q, MacGregor GG, Leng Q, Amorim JB, et al. Maxi-K channels contribute to urinary potassium excretion in the ROMK-deficient mouse model of type II Bartter’s syndrome and in an adaptation to a high K diet. Kidney Int 2006;70:51–59.
Kramer BK, Bergler T, Stoelcker B, Waldegger S. Mechanisms of disease. The kidney specific chloride channels ClCKA, ClCKB, the Barttin subunit, and their clinical relevance. Nat Clin Pract Nephrol 2008;4:38–46.
Jang HR, Lee JW, Oh YK. From bench to bedside. Diagnosis of Gitelman’s syndrome—defect of sodium-chloride cotransporter in renal tissue. Kidney Int 2006;70:813–817.
Colussi G, Bettinelli A, Tedesehi S. A thiazide test for the diagnosis of renal tubular hypokalemic disorders. Clin J Am Soc Nephrol 2007;2:454–460.
Sassen MC, Jeck N, Klaus G. Can renal tubular hypokalemic disorders be accurately diagnosed on the basis of the diuretic response to thiazide? Nat Clin Pract Nephrol 2007;3:528–529.
Mersin SS, Ramelli GP, Laux-End R, Bianchetti MG. Urinary chloride excretion distinguishes between renal and extrarenal metabolic alkalosis. Eur J Pediatr 1995;154:979–982.
Puricelli E, Bettinelli A, Borsa N, Sironi F, Mattiello C, Tammaro F, et al; Italian Collaborative Group for Bartter Syndrome. Long-term follow-up of patients with Bartter syndrome type I and II. Nephrol Dial Transplant 2010;25:2976–2981.
Vaisbich MH, Fujimura MD, Koch VH. Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol 2004;19:858–863.
Chan JCM. Potassium disturbances. In: Lai KN, eds. A Practical Manual of Renal Medicine. Singapore: World Scientific/Imperial College Press, 2009: 39–44.
Trachtman H, Gipson D. Bartter and Gitelman syndromes. NephSAP 2009;8:50–51.
Gill JR Jr, Santos F, Chan JCM. Disorders of potassium metabolism. In: Chan JCM, Gill JR Jr, eds. Kidney Electrolyte Disorders. New York: Churchill Livingstone, 1990: 137–170.
Cortesi C, Lava SA, Bettinelli A, Tammaro F, Giannini O, Caiata-Zufferey M, et al. Cardiac arrhythmias and rhabdomyolysis in Bartter-Gitelman patients. Pediatr Nephrol 2010;25:2005–2008.
Bettinelli A, Borsa N, Syren ML. Simultaneous mutations in the ClCNKB and SLC12A3 genes in two siblings with phenotypic heterogeneity in classic Bartter syndrome. Pediatr Res 2005;58:1269–1273.
Cruz DN, Shafer AJ, Bia MJ, Lifton RP, Simon DB. Gitelman syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 2001;59:710–711.
Sabath E, Meade P, Beckman J. Pathophysiology of functional mutations of the thiazide-sensitive Na-K co-transporter in Gitelman disease. Am J Physiol 2004;287:F195–F203.
Nozu K, Inagaki T, Fu XJ, Nozu Y, Kaito H, Kanda K, et al. Moelcular analysis of digenic inheritance in Bartter syndrome with sensorineural deafness. J Med Genet 2008;45:182–186.
Simon DB, Karet FE, Hamdan JM, DiPetro A, Sanjad SA, Lifton RP. Bartter syndrome, hypokalemic alkalosis with hypercalciuria, is caused by mutation in the Na-K-2Cl trasporter NKCC2. Nat Genet 1996;13:183–188.
Su I, Frank R, Gauthier BG. Bartter syndrome and focal segmental glomerulosclerosis: a possible link between two diseases. Pediatr Nephrol 2000;14:970–972.
Leonhardt A, Timmermans G, Roth B, Seyberth HW. Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome. J Pediatr 1992;120:546–554.
Restrepo de Rovetto C, Welch TR, Hug G, Clark KE, Bergstrom W. Hypercalciuria and Bartter syndrome: evidence for an abnormality of vitamin D metabolism. J Pediatr 1989;115:397–404.
Roth KS. Disorders of membrane transport. In: Sarafoglou K, Hoffmann GF, Roth KS, eds. Pediatric Endocrinology and Inborn Errors of Metabolism. New York: McGraw Hill Med Publishing, 2009: 693–717.
Hebert SC. Bartter syndrome. Curr Opin Nephrol Hyeprtens 2003;12;527–532.
Kleta R, Bockenhauer D. Bartter syndromes and other salt-losing tubulopathies. Nephron Physiol 2006;104:73–80.
Abuladze N, Yanagawa N, Lee I. Peripheral blood mononuclear cells express mutated NCCT mRNA in Gitelman syndrome: evidence for abnormal thiazide-sensitive NaCl cotransport. J Am Soc Nephrol 1998;9:819–826.
Yang SS, Lo YF, Wu CC. SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction. J Am Soc Nephrol 2010;21:1868–1877.
Rodan AR, Huang C. An emerging role for SPAK in NCC, NKCC, and blood pressure regulation. J Am Soc Nephrol 2010;21:1812–1814.
Kral A, O’Donoghue GM. Profound deafness in childhood. N Engl J Med 2010;363:1438–1450.
Ataoglu E, Civilibal M, Ozkul AA, Varal IG, Oktay ER, Murat E. Indomethacin-induced colon perforation in Bartter’s syndrome. Indian J Pediatr 2009;76:322–323.
Marlow N, Chiswick ML. Neonatal Bartter’s syndrome, indomethacin and necrotising enterocolitis. Acta Paediatr Scand 1982;71:1031–1032.
Luthy C, Bettinelli A, Iselin S, Metta MG, Basilico E, Oetliker OH, et al. Normal prostaglandinuria E2 in Gitelman’s syndrome, the hypocalciuric variant of Bartter’s syndrome. Am J Kidney Dis 1995;25:828–829.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fremont, O.T., Chan, J.C.M. Understanding Bartter syndrome and Gitelman syndrome. World J Pediatr 8, 25–30 (2012). https://doi.org/10.1007/s12519-012-0333-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-012-0333-9